{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0003224\nAge: 63\nGender: Female\nSample ID: P-0003224-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nAR c.1225G>A (p.G409R) - in 18.00% of 321 reads\nARID1A c.413C>G (p.S138*) - in 16.00% of 70 reads\nCCNE1 c.79C>T (p.R27C) - in 22.00% of 512 reads\nCDH1 c.2440-1G>A (p.X814_splice) - in 28.00% of 294 reads\nDNMT3B c.1960C>T (p.L654F) - in 16.00% of 682 reads\nESR1 c.1613A>G (p.D538G) - in 20.00% of 416 reads\nGATA3 c.1011dup (p.C338Lfs*14) - in 18.00% of 536 reads\nIGF1R c.3267T>A (p.S1089R) - in 21.00% of 559 reads\nMAP3K1 c.1595G>A (p.R532Q) - in 19.00% of 665 reads\nNF1 c.2323G>A (p.E775K) - in 18.00% of 566 reads\nPIK3CA c.3140A>G (p.H1047R) - in 19.00% of 455 reads\nPIK3CA c.317G>T (p.G106V) - in 22.00% of 631 reads\nPOLE c.52G>A (p.E18K) - in 14.00% of 138 reads\nRAD50 c.3109G>C (p.E1037Q) - in 17.00% of 424 reads\nRICTOR c.1624G>C (p.E542Q) - in 19.00% of 488 reads\nCNA Data:\nCCND1 - High Level Amplification\nFGF4 - High Level Amplification\nFGF3 - High Level Amplification\nFGF19 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n    \"Drug Name\": \"Alpelisib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed on endocrine therapy (implied by advanced/metastatic status with PIK3CA mutation)\",\n    \"Genomic Features\": \"PIK3CA mutation (c.3140A>G, p.H1047R)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf\"\n  }\n}"
}